`To:
`Cc:
`
`Subject:
`Date:
`Attachments:
`
`Hasford, Justin
`Trials
`Diner, Bryan; Goldberg, Joshua; Officer, Kassandra; (Dowty) Robinson, Lauren; Kim, Kyu Yun; Torczon, Richard
`(External); Mills, Jad; Thomas, Tasha; Berman, Richard; Frese, Bradford C.; Christopher J. Sorenson; Andrew O.
`Larsen; Melissa M. Hayworth
`Mylan Pharmaceuticals Inc. v. Bausch Health Ireland Ltd., IPR2022-00722
`Wednesday, August 9, 2023 6:16:32 PM
`image001.png
`
`CAUTION: This email has originated from a source outside of USPTO. PLEASE CONSIDER THE SOURCE before
`responding, clicking on links, or opening attachments.
`
`Dear Board:
`
`Pursuant to 37 C.F.R. 42.123, Patent Owner respectfully requests a conference call to seek
`authorization to submit supplemental information to the Board in IPR2022-00722, in particular the
`expert report of Dr. Zhou that Mylan recently served in Case No. 22-cv-20 (N.D. W.Va.). Counsel for
`Petitioner and Patent Owner met and conferred on August 7, 2023, and Petitioner opposes such
`authorization.
`
`Petitioner’s position is that Patent Owner has not satisfied the standard for the relief requested, and
`that the Zhou report should not be admitted without affording Petitioner an opportunity to provide
`the Board with briefing about its contents and to submit materials relied upon by Dr. Zhou.
`
`Counsel for the parties are available after 9 am Pacific on Friday, August 11 and on Thursday, August
`17.
`
`Respectfully submitted,
`
`Justin Hasford
`
`Justin J. Hasford | Bio
`Partner
`Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
`901 New York Avenue, NW, Washington, DC 20001-4413
`+1 202 408 4000 | fax +1 202 408 4400 | justin.hasford@finnegan.com
`www.finnegan.com | LinkedIn Profile | Finnegan AIA Blog
`
`This e-mail message is intended only for individual(s) to whom it is addressed and may contain information that is privileged, confidential,
`proprietary, or otherwise exempt from disclosure under applicable law. If you believe you have received this message in error, please
`advise the sender by return e-mail and delete it from your mailbox. Thank you.
`
`This e-mail message is intended only for individual(s) to whom it is addressed and may contain information that is privileged, confidential,
`proprietary, or otherwise exempt from disclosure under applicable law. If you believe you have received this message in error, please
`
`Exhibit 3002
`
`
`
`advise the sender by return e-mail and delete it from your mailbox. Thank you.
`
`